Education
About Us
Working with TipRanks
Follow Us
Erasca (ERAS)
NASDAQ:ERAS
ERAS Stock Chart & Stats
$14.10
-$0.05(-2.00%)
At close: 4:00 PM EST
$14.10
-$0.05(-2.00%)
Day’s Range― - ―
52-Week Range$1.01 - $14.63
Previous CloseN/A
Volume148.24K
Average Volume (3M)6.76M
Market Cap
$4.37B
Enterprise Value$4.32B
Total Cash (Recent Filing)$288.40M
Total Debt (Recent Filing)$48.29M
Price to Earnings (P/E)―
Beta2.01
Next Earnings
Mar 19, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding309,586,800
10 Day Avg. Volume8,687,046
30 Day Avg. Volume6,757,213
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)1.39
Price to Sales (P/S)0.00
P/FCF Ratio-4.45
Enterprise Value/Market Cap0.99
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-5.19K
Enterprise Value/Ebitda-34.30
Forecast
1Y Price Target
$10.88Price Target Upside-22.84% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.47
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical PotencyERAS-0015 produced tumor regressions and partial responses across multiple tumor types at markedly lower doses than prior comparators, indicating strong clinical potency that supports further development.
Financial RunwayA sizable equity raise strengthened the balance sheet and provides capital to fund operations through key clinical development milestones.
Safety And Dosing FlexibilityNo dose-limiting toxicities and mostly low-grade side effects across dose levels suggest a manageable safety profile that could allow higher effective dosing without added toxicity.
Bears Say
Clinical CompetitionThe broader RAS inhibitor field includes multiple active programs and unanswered questions about optimal combination strategies, raising development and competitive risk for any single asset.
Durability And Patient SelectionDurability of responses remains uncertain and additional work is needed to identify which RAS-mutant tumors are truly RAS-dependent and most likely to benefit from monotherapy.
Valuation RiskMarket valuation appears to embed a high implied probability of clinical success, meaning definitive clinical readouts will be required to support further upside.
Erasca News
ERAS FAQ
What was Erasca’s price range in the past 12 months?
Erasca lowest stock price was $1.01 and its highest was $14.63 in the past 12 months.
What is Erasca’s market cap?
Erasca’s market cap is $4.37B.
When is Erasca’s upcoming earnings report date?
Erasca’s upcoming earnings report date is Mar 19, 2026 which is in 14 days.
How were Erasca’s earnings last quarter?
Erasca released its earnings results on Nov 12, 2025. The company reported -$0.11 earnings per share for the quarter, missing the consensus estimate of -$0.104 by -$0.006.
Is Erasca overvalued?
According to Wall Street analysts Erasca’s price is currently Overvalued.
Does Erasca pay dividends?
Erasca does not currently pay dividends.
What is Erasca’s EPS estimate?
Erasca’s EPS estimate is -0.11.
How many shares outstanding does Erasca have?
Erasca has 309,586,800 shares outstanding.
What happened to Erasca’s price movement after its last earnings report?
Erasca reported an EPS of -$0.11 in its last earnings report, missing expectations of -$0.104. Following the earnings report the stock price went down -4.151%.
Which hedge fund is a major shareholder of Erasca?
Currently, no hedge funds are holding shares in ERAS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Erasca Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.88 (-22.84% Downside)
$10.88 (-22.84% Downside)
Hedge Fund Trend
Increased
By 343.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 13.0%
Last 30 Days ▲ 13.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
400.50%
12-Months-Change
Fundamentals
Return on Equity
-32.00%
Trailing 12-Months
Asset Growth
-20.51%
Trailing 12-Months
Company Description
Erasca
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.
ERAS Stock 12 Month Forecast
Average Price Target
$10.88
▼(-22.84% Downside)
Technical Analysis
Arcturus Therapeutics
―
Arvinas Holding Company
―
―
Olema Pharmaceuticals
―
Bicara Therapeutics Inc.
―
Ownership Overview
10.90% Insiders
9.98% Mutual Funds
17.06% Other Institutional Investors
53.57% Public Companies and
Individual Investors